A Phase 2 interventional study of Brensocatib and Placebo in Cystic Fibrosis, sponsored by Insmed Incorporated. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Insmed Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 303rd largest by enrollment of the 517 interventional ones that give a count, is one of 36 that started in 2021, is one of 103 in phase 2, and was the 597th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 36 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 8 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female participants with a confirmed diagnosis of CF related lung disease:
Male and female participants must use that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
Have diagnosed periodontal disease and are either:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brensocatib at a dose of 10 mg once per day for 28 days.
Drug: Brensocatib
Participants received brensocatib at a dose of 25 mg once per day for 28 days.
Drug: Brensocatib
Participants received brensocatib at a dose of 40 mg once per day for 28 days.
Drug: Brensocatib
Participants received a placebo matching brensocatib once per day for 28 days.
Drug: Placebo
Oral tablet
Also known as: INS1007
Oral tablet
Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Cmax of Brensocatib on Day 28
Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
Tmax of Brensocatib on Day 28
Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1
Time frame: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 1
AUC0-24 of Brensocatib in Plasma on Day 28
Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose on Day 28
Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28
Time frame: Predose and at 0.5, 1, 2, 4, 6, 8, 24, and 168 hours postdose on Day 28
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
A TEAE is defined as any adverse event (AE) that occurred after the first dose of study investigational medicinal product (IMP) and within 28 days after the last dose of study IMP.
Time frame: Up to Day 56
Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib Cmax After Administration of Brensocatib on Days 1 and 28
Analysis of dose dependency for brensocatib Cmax was performed using a power law model. The logarithm of the Cmax was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.
Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose
Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUC0-24 After Administration of Brensocatib on Days 1 and 28
Analysis of dose dependency for brensocatib AUC0-24 was performed using a power law model. The logarithm of the AUC0-24 was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.
Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, and 24 hours postdose
AUClast of Brensocatib in Plasma on Days 1 and 28
Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose
Dose Proportionality of Brensocatib for Dose Levels 10mg to 40mg Using Brensocatib AUClast, After Administration of Brensocatib on Days 1 and 28
Analysis of dose dependency for brensocatib AUClast was performed using a power law model. The logarithm of the AUClast was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.
Time frame: Day 1: Predose and 0.5, 1, 2, 4, 6, 8, and 24 hours postdose; Day 28: Predose and at 0.5, 1, 2, 4, 6, 8, 24 and 168 hours postdose
Participants took part in the study at investigational sites in the United States.
| Milestone | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo |
|---|---|---|---|---|
| Started | 8 | 8 | 8 | 5 |
| Completed | 8 | 8 | 8 | 5 |
| Not completed | 0 | 0 | 0 | 0 |
| nanograms per milliliter (ng/mL) | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 | 62.4 ± 41.3 | 136 ± 25.9 | 338 ± 17.7 |
| ng/mL | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Cmax of Brensocatib on Day 28 | 86.2 ± 33.1 | 234 ± 37.5 | 469 ± 34.0 |
| hours | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Brensocatib on Day 1 | 2.0 (1.0 to 24.8) | 1.5 (1.0 to 4.1) | 1.5 (0.6 to 24.9) |
| hours | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Tmax of Brensocatib on Day 28 | 1.9 (0.5 to 4.0) | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 4.0) |
| hours*ng/mL | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24) of Brensocatib in Plasma on Day 1 | 792 ± 49.5 | 1600 ± 22.0 | 3510 ± 35.0 |
| hours*ng/mL | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| AUC0-24 of Brensocatib in Plasma on Day 28 | 1050 ± 33.1 | 3640 ± 32.7 | 5950 ± 40.4 |
| hours | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Elimination Half-life (t1/2) of Brensocatib in Plasma on Day 28 | 29.6 ± 16.5 | 32.4 ± 23.0 | 36.0 ± 39.5 |
A TEAE is defined as any adverse event (AE) that occurred after the first dose of study investigational medicinal product (IMP) and within 28 days after the last dose of study IMP.
| Participants | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo |
|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 4 | 5 | 4 | 2 |
Analysis of dose dependency for brensocatib Cmax was performed using a power law model. The logarithm of the Cmax was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.
| log(ng/ml) per log(mg) | Brensocatib 10 mg to 40 mg |
|---|---|
| Day 1 | 1.168 (0.97 to 1.37) |
| Day 28 | 1.206 (1.00 to 1.41) |
Analysis of dose dependency for brensocatib AUC0-24 was performed using a power law model. The logarithm of the AUC0-24 was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.
| log(ng*h/mL) per log(mg) | Brensocatib 10 mg to 40 mg |
|---|---|
| Day 1 | 1.033 (0.80 to 1.26) |
| Day 28 | 1.267 (1.05 to 1.48) |
| hours*ng/mL | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg |
|---|---|---|---|
| Day 1 | 792 ± 49.5 | 1600 ± 22.0 | 3510 ± 35.0 |
| Day 28 | 2210 ± 40.6 | 8220 ± 44.1 | 13700 ± 58.6 |
Analysis of dose dependency for brensocatib AUClast was performed using a power law model. The logarithm of the AUClast was linearly related to the logarithm of the dose using a linear regression analysis. Slope of the regression and corresponding 90% CIs are presented. Slope (90% CI): log(PK parameter) = intercept + slope \* log(dose) + error term, for relationship between each of the dose levels. All 3 dose levels are included in the same model for the dose-exposure relationship.
| log(ng*h/mL) per log(mg) | Brensocatib 10 mg to 40 mg |
|---|---|
| Day 1 | 1.033 (0.80 to 1.26) |
| Day 28 | 1.334 (1.05 to 1.61) |
Collected over Up to Day 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brensocatib 10 mg | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Brensocatib 25 mg | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Brensocatib 40 mg | 0/8 (0%) | 1/8 (12.5%) | 4/8 (50%) |
| Placebo | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Event | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo |
|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/8 | 0/8 | 1/8 | 0/5 |
| Event | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo |
|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/8 | 0/8 | 1/8 | 0/5 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 2/8 | 0/8 | 0/8 | 0/5 |
| HeadacheNervous system disorders | 0/8 | 2/8 | 0/8 | 1/5 |
| Abdominal painGastrointestinal disorders | 0/8 | 0/8 | 1/8 | 1/5 |
| Abdominal pain upperGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 1/5 |
| GastroenteritisGastrointestinal disorders | 0/8 | 0/8 | 0/8 | 1/5 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/8 | 0/8 | 0/8 | 1/5 |
| COVID-19Infections and infestations | 0/8 | 1/8 | 1/8 | 0/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/8 | 1/8 | 0/8 | 0/5 |
| LymphadenopathyBlood and lymphatic system disorders | 0/8 | 1/8 | 0/8 | 0/5 |
Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 38.3 ± 14.86 | 42.9 ± 16.54 | 34.6 ± 15.95 | 34.6 ± 9.79 | 37.9 ± 14.59 |
| Sex: Female, Male(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 2 | 5 | 2 | 2 | 11 |
| Male | 6 | 3 | 6 | 3 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 1 | 4 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 7 | 7 | 4 | 25 |
| Race (NIH/OMB)(Participants) | Brensocatib 10 mg | Brensocatib 25 mg | Brensocatib 40 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| White | 7 | 8 | 6 | 5 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Nov 2022, 11 months.
Results were first posted in Mar 2026, 3 years 4 months after primary completion. A results delay was requested in Oct 2023.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 11 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brensocatib